Ultra-high-risk group of multiple myeloma: a real-world study based on two different prognostic evaluation systems

Abstract Background: Recently, two prognostic evaluation systems based on different angles, UK Myeloma Research Alliance proposed UK Myeloma Research Alliance Risk Profile(MRP) and chinese inflammatory prognostic scoring index(IPSI), have shown prognostic differences in newly diagnosed multiple myeloma(MM) patients without transplantation. However, there is no relevant research on whether there is a difference in the evaluation of the two systems. Methods: The study used these two systems to evaluate the prognosis of 160 patients with MM based on bortezomib without transplantation from January 2007 to June 2018. Results: It was found that the evaluation of patients at medium and low risk was similar, but in the high-risk group of MRP, IPSI could be further stratified, and in the high-risk group of IPSI, MRP could also be further stratified. Conclusions: It is suggested that myeloma patients with high risk factors of MRP and IPSI are ultra high risk patients with poor prognosis.